arrow
D

Daniel Sasca

mcmaster university
H指数:13
被引数:1,012

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials

卡那奴单抗或依马伏塞替治疗低危骨髓增生异常综合征贫血:CANFIRE和LUCAS两项2期、开放标签、多中心试验的结果

2026-09-160
OAAI
Type I interferon–activated NK cells control polycythemia vera in vivo

I型干扰素激活的NK细胞在体内控制原发性红细胞增多症

Blood
IF23.1
2026-06-040
PRE
Synergistic Efficacy of Dual Menin and PRMT5 Targeting Against NPM1 mutated and KMT2A- rearranged Leukemia

双Menin和PRMT5靶向治疗NPM1突变型和KMT2A重排型白血病的协同疗效

BLOOD
IF23.1
2024-11-050
PRE
Acute Resistance to BET Inhibitors Remodels Compensatory Transcriptional Programs Via p300 Co-Activation

急性对BET抑制剂的耐药性通过p300协同激活重塑补偿性转录程序

BLOOD
IF23.1
2024-11-050
PRE
Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma
LEUKEMIA
IF13.4
2023-08-303
OAAI
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax
2023-04-2722
OAAI
Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression
2021-09-2323
OAAI
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
2019-03-1993
OAAI
Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors
2017-08-2154
OA